CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- FinancialsAltman Z-Score 13.09: safe zone
- Interpretations3 currently firing — 3
Sign in to view price data.
Sign inWhat the company actually pays, and whether its own cash supports it.
Dividends view
Yield
1.04%
Annual Rate
CNY 0.40Paid semi-annual
Payout Ratio
156.3%High
Last Ex-Dividend
Jul 16, 2026
The reported statements, read against the company's own industry.
Financials view
Market Capitalization
6.19BCNY919.07M · vs all stocks (USD)
Trailing P/E
147.84xvs Biotechnology peers
Revenue (TTM)
691.21MCNY102.66M · vs all stocks (USD)
Profit Margin
6.67%vs Biotechnology peers
Beta
0.8930xvs all stocks
52-Week Change
27.06%vs all stocks
Forward Annual Dividend Yield
1.04%vs all stocks
Market Capitalization
6.19BCNY919.07M · vs all stocks (USD)
Enterprise Value
6.67BCNY990.25M · vs all stocks (USD)
Trailing P/E
147.84xvs Biotechnology peers
Forward P/E
80.77xvs Biotechnology peers
Price to Sales (TTM)
9.68xvs Biotechnology peers
Price to Book (MRQ)
6.42xvs Biotechnology peers
Enterprise to Revenue
9.65xvs Biotechnology peers
Enterprise to EBITDA
115.99xvs Biotechnology peers
Gross Margin
31.92%vs Biotechnology peers
Profit Margin
6.67%vs Biotechnology peers
Operating Margin
9.77%vs Biotechnology peers
Return on Assets (TTM)
1.35%vs Biotechnology peers
Return on Equity (TTM)
4.44%vs Biotechnology peers
Revenue (TTM)
691.21MCNY102.66M · vs all stocks (USD)
Revenue per Share (TTM)
3.83CNYUpdated Aug 20, 2026Quarterly Revenue Growth
1.70%vs Biotechnology peers
Gross Profit (TTM)
183.72MCNY27.29M · vs all stocks (USD)
EBITDA (TTM)
97.07MCNY14.42M · vs all stocks (USD)
Net Income (TTM)
46.10MCNY6.85M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
98.60%vs Biotechnology peers
Operating Cash Flow (TTM)
167.14MCNY24.82M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
44.76MCNY6.65M · vs all stocks (USD)
Forward Annual Dividend Rate
0.4000CNYUpdated Aug 20, 2026Forward Annual Dividend Yield
1.04%vs all stocks
Trailing Annual Dividend Rate
0.2769CNYUpdated Aug 20, 2026Trailing Annual Dividend Yield
0.72%vs all stocks
Payout Ratio
156.25%vs Biotechnology peers
Revenue
688.35MCNYFY2025 · Dec 31, 2025Cost of Goods Sold
499.63MCNYFY2025 · Dec 31, 2025Gross Profit
188.72MCNYFY2025 · Dec 31, 2025Operating Income
43.62MCNY6.48M · vs all stocks (USD)
Pre-tax Income
28.32MCNYFY2025 · Dec 31, 2025Income Tax Expense
-5.98MCNYFY2025 · Dec 31, 2025Net Income
34.29MCNYFY2025 · Dec 31, 2025EBIT
36.61MCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
97.07MCNYFY2025 · Dec 31, 2025Research & Development
37.15MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
23.04MCNYFY2025 · Dec 31, 2025Other Operating Expenses
3.93MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
1.50MCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
8.29MCNYFY2025 · Dec 31, 2025EPS (Basic)
0.2500CNYFY2025 · Dec 31, 2025EPS (Diluted)
0.2400CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
137.18MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
137.18MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
34.29MCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
34.40MCNYFY2025 · Dec 31, 2025Free Cash Flow
-8.79MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
52.82MCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
34.29MCNYFY2025 · Dec 31, 2025Other Non-cash Items
49.33MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-16.79MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-32.43MCNYFY2025 · Dec 31, 2025Capital Expenditures
-43.19MCNYFY2025 · Dec 31, 2025Purchase of Investments
-23.30MCNYFY2025 · Dec 31, 2025Sale of Investments
23.11MCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
-43.39MCNYFY2025 · Dec 31, 2025Long-term Debt Issuance
25.66MCNYFY2025 · Dec 31, 2025Long-term Debt Payments
-25.66MCNYFY2025 · Dec 31, 2025Common Dividends Paid
-54.04MCNYFY2025 · Dec 31, 2025Other Financing Charges
-25.82MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
-79.87MCNYFY2025 · Dec 31, 2025Shares Outstanding
181.46MSharesUpdated Aug 20, 2026Float Shares
96.85MSharesUpdated Aug 20, 2026% Held by Insiders
45.66%vs all stocks
% Held by Institutions
6.81%vs all stocks
Total Cash (MRQ)
288.16MCNY42.80M · vs all stocks (USD)
Total Cash per Share (MRQ)
1.61CNYUpdated Aug 20, 2026Total Debt (MRQ)
159.36MCNY23.67M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.1547xvs Biotechnology peers
Current Ratio (MRQ)
3.76xvs Biotechnology peers
Book Value per Share (MRQ)
5.76CNYUpdated Aug 20, 2026Total Assets
1.31BCNY195.17M · vs all stocks (USD)
Total Current Assets
582.10MCNYFY2025 · Dec 31, 2025Total Liabilities
309.87MCNYFY2025 · Dec 31, 2025Total Non-current Assets
732.00MCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
137.66MCNYFY2025 · Dec 31, 2025Total Current Liabilities
172.21MCNYFY2025 · Dec 31, 2025Cash
59.11MCNYFY2025 · Dec 31, 2025Cash Equivalents
0.00CNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
59.11MCNYFY2025 · Dec 31, 2025Other Short-term Investments
248.98MCNYFY2025 · Dec 31, 2025Accounts Receivable
147.01MCNYFY2025 · Dec 31, 2025Inventory
74.05MCNYFY2025 · Dec 31, 2025Accounts Payable
62.56MCNYFY2025 · Dec 31, 2025Short-term Debt
36.00MCNYFY2025 · Dec 31, 2025Other Current Liabilities
3.49MCNYFY2025 · Dec 31, 2025Long-term Debt
129.30MCNYFY2025 · Dec 31, 2025Other Non-current Liabilities
3.98MCNYFY2025 · Dec 31, 2025Common Stock (Book)
139.59MCNYFY2025 · Dec 31, 2025Retained Earnings
109.84MCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
1.00BCNY149.15M · vs all stocks (USD)
Treasury Stock
53.08MCNYFY2025 · Dec 31, 202552-Week Low
22.23CNYUpdated Aug 20, 202652-Week High
52.28CNYUpdated Aug 20, 202652-Week Change
27.06%vs all stocks
Beta
0.8930xvs all stocks
50-Day MA
28.81CNYUpdated Aug 20, 2026200-Day MA
29.67CNYUpdated Aug 20, 2026Avg 10-Day Volume
26.17MSharesUpdated Aug 20, 2026Avg 30-Day Volume
19.05MSharesUpdated Aug 20, 2026Diluted EPS (TTM)
0.2500CNYUpdated Aug 20, 20263 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsHow does this company use capital?
Industry-Benchmarked Return on Capital Elevated
It earns more on its assets and its equity than its industry, and gets more sales from those assets.
Reads
Revenue Growing With Receivables Growing
Revenue has risen three years, and what customers owe has risen with it.
Reads
Minimal Tax and Interest Drag
Almost nothing is lost between its operating profit and its net income.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Financial Health
Altman Z-Score 13.09: safe zoneNotable
Altman Z-Score: 13.09
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Companies that share the same coordination system — how they create, deliver, or capture value.
L&C Bio Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Hunan Jiudian Pharmaceuticals Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Beijing SL Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Geron Corporation
Tier 1ProductionApproval-Gated PipelineRule
Wuhan Huakang Century Medicine Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Wanbangde Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Wuhan Keqian Biology Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Hangzhou Biotest Biotech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
China Isotope & Radiation Corporation
Tier 1ProductionApproval-Gated PipelineRuleFlow
Shandong Wit Dyne Health Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Corcept Therapeutics Incorporated
3 interpretationsIndustry-Benchmarked Return on Capital ElevatedRevenue Growing With Receivables GrowingMinimal Tax and Interest Drag
Hanwha Aerospace Co., Ltd.
3 interpretationsIndustry-Benchmarked Return on Capital ElevatedRevenue Growing With Receivables GrowingMinimal Tax and Interest Drag
Sk Biopharmaceuticals Co., Ltd.
3 interpretationsIndustry-Benchmarked Return on Capital ElevatedRevenue Growing With Receivables GrowingMinimal Tax and Interest Drag